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Malaria is a devastating infectious disease, which causes over 400,000
deaths per annum and impacts the lives of nearly half the world’s
population. The causative agent, a protozoan parasite, replicates
within red blood cells (RBCs), eventually destroying the cells in a lytic
process called egress to release a new generation of parasites. These
invade fresh RBCs to repeat the cycle. Egress is regulated by an es-
sential parasite subtilisin-like serine protease called SUB1. Here, we
describe the development and optimization of substrate-based pep-
tidic boronic acids that inhibit Plasmodium falciparum SUB1 with low
nanomolar potency. Structural optimization generated membrane-
permeable, slow off-rate inhibitors that prevent P. falciparum egress
through direct inhibition of SUB1 activity and block parasite replication
in vitro at submicromolar concentrations. Our results validate SUB1 as
a potential target for a new class of antimalarial drugs designed to
prevent parasite replication and disease progression.
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Malaria, a disease caused by obligate intracellular parasites ofthe genus Plasmodium, is a global health problem threatening
more than half the earth’s population (1). Recent decades have
seen a considerable reduction in the incidence of clinical malaria
and malaria-related mortality, largely due to the availability of ef-
ficacious chemotherapies and control of the mosquito vector (2).
However, efforts toward malaria eradication are impeded by the
alarming spread of drug-resistant parasites, rendering existing drugs
ineffective in many regions (3, 4). Of particular concern, resistance
has now been reported to nearly all clinically used antimalarial
drugs including artemisinins, the current front line drug class (5).
There is therefore an urgent need to bolster the antimalarial drug
arsenal with new chemotherapeutics, particularly those with as yet
unexploited mechanisms of action.
Clinical malaria results from repeated rounds of replication of
the parasite in circulating red blood cells (RBCs). Merozoites
invade the cells and divide asexually within a membrane-bound
parasitophorous vacuole (PV) to produce a mature multinucle-
ated form called a schizont. This then undergoes segmentation to
generate 16 or more daughter merozoites, which are eventually
released through a lytic process called egress, in the process
destroying the infected RBC. Shortly before egress, activation of a
parasite cyclic GMP-dependent protein kinase called PKG induces
the discharge of a subtilisin-like serine protease called SUB1 from
specialized merozoite secretory organelles called exonemes (6, 7).
Upon its release into the PV lumen, SUB1 rapidly cleaves and
activates a number of PV-resident and merozoite surface proteins,
leading within minutes to explosive rupture of the PV membrane
(PVM) and RBCmembrane to allow merozoite release (8–12). The
free parasites immediately invade fresh RBCs to repeat the cycle.
All Plasmodium species, including the most important human
malaria pathogens Plasmodium falciparum, Plasmodium vivax, and
Plasmodium knowlesi, possess a single ortholog of SUB1 with
similar (though not identical) substrate specificity (13). Genetic
experiments have shown that SUB1 is indispensable for parasite
survival, with SUB1 gene disruption leading in asexual blood
stages and the preceding liver stages of infection to a complete
block in merozoite egress (12, 14, 15). This, together with the lack
of structural resemblance of SUB1 to human serine proteases (16,
17), has focused interest on SUB1 as an attractive pharmacological
target for antimalarial drug discovery. However, the identification of
potent drug-like SUB1 inhibitors has proven to be a difficult task.
Attempts to identify ligands of SUB1 by screening of synthetic or
natural product libraries, and through in silico screening, met with
limited success (6, 18, 19), probably due to the relatively shallow and
elongated cavity of the enzyme active site (16, 17). We have pre-
viously reported the rational design of peptidic ketoamide inhibitors
of P. falciparum SUB1 (PfSUB1) based on the substrate specificity
of the enzyme (Fig. 1) (13, 20). Preliminary structure-activity rela-
tionships analysis of these inhibitors revealed a tetrapeptide mimic
on the nonprime side and an oxycarbonylethyl group on the prime
side as structural features required to attain submicromolar inhibi-
tory potency. Given the capacity of boronic acids to form strong
covalent but reversible bonds with the catalytic Ser residue of serine
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proteases, here we have investigated peptidic boronic acids as
PfSUB1 inhibitors. These efforts have generated nanomolar PfSUB1
inhibitors that can access PfSUB1 in the intraerythrocytic parasite
and prevent parasite replication through direct inhibition of egress.
Results
Discovery of Potent Substrate-Based Peptidyl Boronic Acid Inhibitors
of PfSUB1. We previously described the development of a
fluorescence-based in vitro assay suitable for the evaluation of
substrate-based PfSUB1 inhibitors, using recombinant PfSUB1
(rPfSUB1) and fluorogenic peptide substrates based on cleavage
sites within endogenous protein substrates of PfSUB1 (13, 21). In
our earlier work (13, 20), we used the assay to identify a substrate-
based pentapeptidic α-ketoamide with a P4 Ile residue and P2 Gly
residue as our most potent inhibitor 1 (IC50 ∼900 nM; Fig. 1).
Unfortunately, this and related α-ketoamides showed no anti-
parasite activity in vitro. This was perhaps unsurprising due to the
high molecular mass and polar nature of these compounds, in-
cluding the presence of a carboxylic acid moiety that was designed
to mimic endogenous PfSUB1 protein substrates by interacting
with the basic S’ surface of the PfSUB1 active-site cleft (16).
Collectively, these features likely rendered the compounds poorly
membrane penetrant.
To build on that work, we first explored a range of P4 substit-
uents of the N-acetyl peptidyl α-ketoamide scaffold, maintaining
the P1 Ala, P2 Gly, and P3 Thr sidechains unaltered. Replacement
of the P4 Ile side chain with a cyclopentane improved potency,
resulting in an peptidic α-ketoamide 2a with an IC50 ∼370 nM (SI
Appendix, Table S1). Reasoning that the exploration of alternative
warheads with known activity against serine proteases might prove
fruitful, we replaced the α-ketoamide functionality of this com-
pound with a boronic acid warhead, in the process removing the
prime side carboxylate. This resulted in compound 3a, which
gratifyingly demonstrated an ∼sevenfold increase in potency over
the best α-ketoamide (Table 1). Combining the features of the
α-ketoamide and compound 3a by adding back the P4 cyclopentane
improved potency by a further ∼13-fold, leading to the low nano-
molar IC50 compound 3b (Table 1).
To examine the importance of the stereochemistry of the ami-
noboronic acid substructure at the P1 position, the PfSUB1 inhib-
itory potency of boronic acid epimer 3c was examined (Table 1). We
found that 3c was significantly less potent than 3b (Table 1), indi-
cating the requirement for a chiral center configuration matching
that of the L-amino acid in native substrates of SUB1. We therefore
maintained this stereochemistry in all subsequent boronic acid
analogs.
Further work focused on enhancing the potency of the com-
pound 3b structural template. Removal of the methyl side chain at
the P1 subsite (compound 3d) reduced potency by eightfold. On
the other hand, attempts to improve potency by exploring extended
alkyl or phenyl substituents at the P1 subsite (compounds 3e, 3f, 3g,
and 3h) met with only limited success, although compound 3e
bearing a hydroxyethyl substituent displayed ∼twofold increased
potency over compound 3b. This appears to contradict earlier
substrate specificity studies, which indicated a preference for the S1
subpocket of PfSUB1 to accommodate polar sidechains (13). The
observation may be explained by a preference of nucleophilic
P1 side-chain residues to form cyclic boronic acids, preventing the
polar hydroxyl group from engaging in interactions with the
enzyme.
Conditional gene disruption experiments have shown that
PfSUB1 is essential for asexual blood-stage parasite survival
in vitro (12). To assess the capacity of the compounds to inter-
fere with parasite replication, we used an in vitro growth assay,
which exploits the DNA-binding fluorescent dye SYBR Green I
to measure parasite proliferation in human RBCs (which do not
possess a nucleus) (22). This showed that while all the com-
pounds inhibited parasite replication, with EC50 values as low as
1.8 μM, there was a poor correlation between growth inhibition
and the PfSUB1 enzyme-inhibitory potency of the compounds
(Table 1). In particular, the most potent inhibitor of PfSUB1
enzymatic activity, compound 3e, was more than sixfold less
growth inhibitory than compound 3b. We reasoned that the polar
nature of 3e likely limits its membrane permeability. It was con-
cluded that this set of compounds suffered from poor access to
PfSUB1 within the intracellular parasite, probably due to low
cellular permeability.
P3 Modification Results in Peptidic Boronic Acids with Submicromolar
Parasite Growth Inhibitory Activity. To seek insights into how the
most potent PfSUB1-inhibitory compounds of this first boronic
acid series might be accommodated into the PfSUB1 active-site
groove, we took advantage of the X-ray crystal structure of
PfSUB1 (16) to perform in silico molecular docking of compounds
(3b and 3e; Fig. 2). We examined the bound molecules in a docked
pose in which the boron atom was involved in a tetrahedrally co-
ordinated intermediate involving the catalytic His428 (Ne2H) and
the oxyanion hole partner N520 (Nδ) and engaged in a covalent
bond with the Oγ of the catalytic Ser606 of PfSUB1. This showed
conservation of the substrate-enzyme canonical H-bond pattern,
with the inhibitor peptidic backbone interacting with PfSUB1 res-
idues Gly467 (NH), Ser490 (NH), and Ser492 (NH). For both
inhibitors, the P4 cyclopentane was nicely accommodated into the
S4 pocket (shaded green for hydrophobicity and delimited by a
thick solid line to indicate optimal steric filling in Fig. 2B). The
inhibitor 3b P1 Ala side chain did not fill the S1 pocket entirely
(indicated by the absence of a solid line at the bottom of the S1
pocket) but occupied the hydrophobic part of the pocket. In the
case of inhibitor 3e, docked in the form of an acyclic boronic acid,
the P1 hydroxyethyl extension filled the S1 pocket fully and was
stabilized by hydrogen bonding with Ser490 Oγ and Ser492 Oγ at
the bottom of the pocket. Despite this, little improvement in po-
tency of inhibitor 3e over inhibitor 3a was observed, which as
mentioned above we suspect is likely explained by compound 3e
adopting the preferential cyclic form of the boronic acid.
Consistent with the X-ray crystal structure of PfSUB1, which
includes its propeptide bound into the active-site groove of the
catalytic domain in a substrate-like manner, the P3 Thr side chain
Fig. 1. Development of rationally designed peptidic PfSUB1 inhibitors.
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of the docked compounds 3b and 3e was observed to extend into
solvent, with no significant contacts with the molecular surface of the
PfSUB1 catalytic domain. Interestingly, however, in both docking
poses we noticed potential for modifying and/or extending the P3
side chain (openness depicted in gray in the two-dimensional dia-
gram) in order to promote hydrophobic interactions with the side-
chain carbon atoms of Lys465 and Leu466 that line the side of the S3
pocket. In silico replacement of the P3 Thr with Val supported this,
revealing potential hydrophobic interactions between the Val P3 side
chain and the side chains of Leu466 and Lys465 (Fig. 2B).
In accord with this, we prepared compounds 3i and 3j in which
the P3 Thr of compound 3b was replaced, respectively, with an
Ala and Val side chain (Table 1). The new compounds showed
slightly improved (3i; IC50 ∼7.8 nM) or nearly twofold im-
proved (3j; IC50 ∼5.7 nM) potency relative to compound 3b in
the in vitro PfSUB1 enzyme assay. Significantly, compounds 3i
and 3j displayed ∼10-fold improved growth inhibitory potency
in the SYBR Green I parasite growth assay, likely due to their
increased lipophilicity, which was expected to confer better
membrane permeability.
Table 1. PfSUB1 enzyme inhibitory and parasite growth inhibitory potency of peptidic boronic acids
Entry Compound Structure IC50 (nM) (rPfSUB1)* EC50 (μM) (parasite growth)†
1 3a 69.4 ± 1.2 1.8 ± 0.6
2 3b 9.3 ± 0.5 2.3 ± 1.4
3 3c 60.1 ± 2.1 18.4 ± 1.8
4 3d 54.3 ± 1.1 1.9 ± 0.4
5 3e 4.6 ± 0.1 15.0 ± 3.6
6 3f 204.2 ± 7.5 N.D.
7 3g 18.7 ± 1.3 N.D.
8 3h 112.0 ± 2.3 N.D.
9 3i 7.8 ± 0.3 0.34 ± 0.08
10 3j 5.7 ± 0.1 0.26 ± 0.06
*IC50 values were determined by quantifying inhibition of rPfSUB1-mediated proteolytic cleavage of a fluorogenic peptide substrate. Values are mean
averages from at least three independent measurements ± SD.
†EC50 values were obtained by quantifying inhibition of P. falciparum growth in vitro over a period of 96 h (two erythrocytic growth cycles) using the DNA-
binding fluorescent dye SYBR Green I to measure parasite replication (22). Values are mean averages from at least three independent measurements ± SD.
N.D., not determined.
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Fig. 2. Substrate-based development of peptidic boronic acid inhibitors of PfSUB1. (A) ICM-Pro best docking poses for the PfSUB1-inhibitory compounds 3b
(ICM-Pro score −27), 3e (ICM-Pro score −32), and 3j (ICM-Pro score −34) in the active site of PfSUB1 (4LVN). The inhibitors are represented as colored balls and
sticks. Hydrogen atoms are shown, while hydrogen bond interactions are indicated (dotted lines). The enzyme molecular surface is shown in transparent
mode (green, hydrophobic; blue, hydrogen bond donor; and red, hydrogen bond acceptor). ICM docking score values below −32 (unitless) are considered
good docking scores. (B) Corresponding two-dimensional interaction diagrams, with green shading for hydrophobic regions, blue shading for hydrogen bond
acceptors, gray dashed arrows for hydrogen bonds (including length in Å), broken thick lines around ligand shape for accessible surfaces, and gray parabolas
for large accessible surface areas. Interacting PfSUB1 residues are labeled and enclosed in oval shapes, the size of which varies depending on the degree of
residue contribution. In all cases, the ligand boron atom is shown covalently bound to the active-site Ser606 Oγ through a boron ester bond, and positions of
the S1 and S4 PfSUB1 active-site pockets are indicated. The P3 position is annotated in red in B.
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Inhibition of P. falciparum Egress by Selective Peptidic Boronic Acids
that Access PfSUB1 in Intracellular Parasites. To determine their
mode of action, the four most potent growth inhibitory compounds
were next evaluated using very short-term cell-based assays focused
on the narrow window within the asexual blood-stage lifecycle
during which the parasite undergoes egress from host RBCs and
invasion into fresh cells. For this, P. falciparum cultures containing
synchronous, highly mature schizonts were supplemented with
compounds 3b, 3e, 3i, and 3j at a range of dilutions, then allowed to
undergo egress and invasion for just 4 h in the continued presence
of the compounds, before assessing formation of newly invaded
“ring” stage parasites by flow cytometry. This confirmed a dose-
dependent inhibitory effect on the transition from schizont to ring
stage, with the relatively lipophilic compounds 3i and 3j displaying
similar EC50 values that were significantly lower than those of 3b
and 3e (Fig. 3A). Microscopic examination of the cultures revealed
schizonts arrested by compounds 3i and 3j, confirming inhibition of
schizont rupture. Importantly, the arrested schizonts were mor-
phologically indistinguishable from those arrested by the reversible
PKG inhibitor (4-[7-[(dimethylamino)methyl]-2-(4-fluorphenyl)imi-
dazo[1,2-α]pyridine-3-yl]pyrimidin-2-amine (C2)), appearing as
segmented forms trapped within an apparently intact PVM and
RBC membrane (Fig. 3B). This egress-arrest phenotype is similar
to that obtained by genetic disruption of PfSUB1 and was clearly
different from that following arrest by the cysteine protease in-
hibitor E64 (Fig. 3B), which does not inhibit PfSUB1 directly but
which blocks a cysteine protease-dependent step in egress fol-
lowing SUB1 discharge and PVM rupture (12).
Examination of the inhibitory activity of compound 3j against
the mammalian trypsin-family serine proteases trypsin, chymo-
trypsin, and elastase revealed a high degree of selectivity for
PfSUB1 (>>100-fold; SI Appendix, Figs. S1–S3), encouraging us
to focus subsequent work on this compound. To directly visualize
the inhibitory effects of compound 3j on parasite egress and to
examine the reversibility of inhibition, we used live time-lapse
video microscopy to observe the behavior of schizonts exposed
to the compound for just 1 h immediately prior to egress. For this,
we used a transgenic parasite line expressing a PVM protein
(EXP2) fused with the green fluorescent protein mNeon Green,
facilitating real-time visualization of PVM integrity as previously
reported by Glushakova and colleagues (23). As shown in Fig. 4A
and Movie S1, this clearly demonstrated significant inhibition of
PVM rupture and egress in parasites treated with 3j, with no signs
of egress even 30 min following washout of the compound. Im-
portantly, 3j-treated parasites remained viable, as shown by their
continued capacity to incorporate the vital mitochondrial dye
MitoTracker Red CMXRos (24) (SI Appendix, Fig. S4), but showed
no signs of the PVM rounding and other morphological changes
that typically precede egress (23, 25), indicating a complete and
selective block in the egress pathway. These egress-associated
transitions were also absent from PfSUB1-null parasites (12), indi-
cating that the effects of 3j closely mimic genetic disruption of
PfSUB1. Further extended incubation of the treated, washed
schizonts with fresh RBCs resulted in only very limited appearance
of new ring stage parasites (Fig. 4B). This confirmed that even
short-term treatment with compound 3j could dramatically impede
parasite escape from the host RBC and that the egress inhibition
over these timescales was effectively irreversible.
These results suggested that compound 3j can access and inhibit
PfSUB1 in an intracellular location (i.e., within the intraerythrocytic
parasite, or in the PV, or both). To seek unambiguous confirmation
that PfSUB1 is the intracellular target of compound 3j, we exam-
ined the effects of the compound on the PfSUB1-mediated pro-
teolytic processing of the established endogenous PfSUB1 substrate
SERA5, an abundant parasite PV protein that only becomes ac-
cessible to cleavage upon discharge of PfSUB1 into the PV in
the minutes leading up to egress and is then released in a processed
form into culture supernatants (6, 11, 12). As shown in Fig. 4C,
treatment with compound 3j reproducibly prevented proteolytic
processing and release of SERA5 into culture supernatants in a
dose-dependent manner, even following compound washout. Cru-
cially, at higher concentrations of the drug where egress and release
of processed SERA5 was completely blocked, no intracellular
Fig. 3. Peptidic boronic acid PfSUB1 inhibitors prevent P. falciparum egress.
(A) Dose–response curves showing ring formation following incubation of
highly mature 3D7 schizonts with RBCs for 4 h in the presence of the indi-
cated compounds. Values are means of three independent experiments.
Calculated EC50 values were as follows: compound 3b, 12.7 ± 0.8 μM; 3e,
15.7 ± 2.5 μM; 3i, 2.0 ± 0.1 μM; and 3j 2.5 ± 0.3 μM. Error bars, SD. (B) Light
micrographs of Giemsa-stained thin films prepared from selected cultures
similar to those described in A, sampled prior to start or following the 4 h
incubation step. Extensive ring formation is evident in the control culture
(examples indicated by arrows). In contrast, cultures containing compounds
3i or 3j (10 μM) show arrest of unruptured schizonts with no ring formation.
Note that the phenotype of the 3i- or 3j-arrested schizonts is similar to that
of C2-treated parasites but distinct from those arrested by the cysteine
protease inhibitor E64, where PVM rupture occurs allowing release of the
enclosed merozoites into the RBC cytosol. (Scale bar, 20 μm.)
Lidumniece et al. PNAS | 5 of 9










processing of SERA5 was evident in the intact egress-arrested
schizonts. Quantitation of egress in these same washout assays by
measuring release of residual hemoglobin from the rupturing
schizonts showed an EC50 of ∼2 μM (Fig. 4D), similar to the EC50
value for new ring generation previously determined by flow
cytometry (Fig. 3A). It was concluded that compound 3j prevents
egress and parasite proliferation through direct inhibition of
intracellular PfSUB1.
An Optimized Membrane-Penetrant Peptidic Boronic Acid Displays
Time-Dependent, Slowly Reversible Binding Kinetics to PfSUB1. Bo-
ronic acids form reversible covalent bonds with serine and threo-
nine proteases (26). Inhibition is generally time dependent, and the
covalent nature of the binding can result in relatively long target
occupancy times despite the reversibility of the bond. That this
might be the case with compound 3j binding to PfSUB1 was ini-
tially suggested by our washout experiments (Fig. 4), which showed
that egress inhibition by compound 3j following washout was much
longer lasting than the rapidly reversible egress inhibition mediated
by C2. To analyze the kinetic characteristics of the interaction
between 3j and rPfSUB1, we used progress curve analysis to con-
tinuously monitor rPfSUB1-mediated cleavage of a fluorogenic
substrate in the presence of a range of concentrations of 3j. As
shown in SI Appendix, Fig. S5, under conditions where substrate
cleavage in the absence of inhibitor (control reaction) displayed a
linear relationship with time, indicating negligible substrate de-
pletion, progress curves in the presence of compound 3j became
progressively nonlinear, characteristic of slow-binding (time-
dependent) inhibition. Under such conditions, fit of the progress
curves by nonlinear regression to Eq. 1 (seeMaterials and Methods)
allows determination of kobs, the pseudo first-order rate constant
for onset of inhibition. The kobs is effectively a composite of the on
and off rates, so least linear squares regression of the calculated
kobs values against inhibitor concentration allows determination of
values of the pseudo first-order dissociation rate constant koff and
the second-order association rate constant kon for the inhibitor-
rPfSUB1 interaction, based respectively on values from the
y-intercept and slope. The y-intercept value corresponds to a koff of
3.7 × 10−4 s−1, which equates to a t1/2
off (bound half-life) of ∼31
min. The calculated kon value was 3.6 × 10
5 M−1.s−1, allowing
calculation of an apparent equilibrium inhibition constant KI
kin
(koff/kon) of 1.0 nM. It was concluded that compound 3j is a potent,
slowly reversible inhibitor of PfSUB1, completely consistent with
the washout data.
Discussion
Prior to parasite egress from the confines of its host RBC, SUB1
is stored in membrane-bound merozoite secretory organelles
called exonemes before its discharge into the PV lumen minutes
before egress to encounter its endogenous substrates. As a result,
in order to gain access to the intracellular enzyme prior to
Fig. 4. Washout experiments show that peptidic boronic acid 3j is a membrane-permeable inhibitor of PfSUB1 and P. falciparum egress. (A) Stills from time-
lapse video microscopic monitoring of purified schizonts following washout of the indicated treatments. The parasites express an mNeonGreen fusion of the
PVM protein EXP2. Washout of drug from schizonts arrested with the reversible PKG inhibitor C2 (1 μM) resulted in normal egress, initiating at ∼6.5 min
following washout. In contrast, no egress occurred over the course of 30 min following washout of parasites treated with saturating amounts (10 μM) of
compound 3j, and there was no discernible change in shape or integrity of the PVM (although slight time-dependent photobleaching of the fluorescence
signal is evident). Identical results were obtained in four independent experiments. (Scale bar, 20 μm.) Also reference Movies S1 and S2. (B) Ring formation
following incubation with fresh RBCs of schizonts pretreated with vehicle only (DMSO), C2 (1 μM), or compound 3j. Drugs were washed away before addition
of RBCs. Ring production was assessed at 24 h. Parasitaemia was also assessed at 48 h to ensure that the rings detectable at 24 h were viable. No rings were
produced by the 10 μM 3j pretreated schizonts, whereas schizonts pretreated with the reversible PKG inhibitor C2 produced rings efficiently. Results shown
are from three independent experiments in different batches of blood. Error bars, ± SD. (C) Western blot analysis of mature schizonts and culture super-
natants thereof following pretreatment for 4 h with compound 3j at the indicated concentrations, then washout before analysis of egress. The parasite PV
protein SERA5, which is proteolytically converted to the P50 fragment through the action of PfSUB1, appeared in the supernatants of control schizonts (which
underwent egress) but remained intracellular in its intact, full-length form at higher concentrations of 3j. As expected, SERA5 processing was also blocked by
C2 (positive control). (D) Quantitation of hemoglobin release into culture supernatants (an indicator of the extent of egress) in the assay analyzed in C. Error
bars, SD. Data shown are typical of four independent experiments.
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substrate cleavage, exogenously applied inhibitory compounds
likely need to cross at least two and as many as four distinct
biological membranes: the RBC membrane, the PVM, the par-
asite plasma membrane, and the exoneme membrane (Fig. 5).
This poses particular challenges for the design of substrate-based
inhibitors. In the case of covalent modifying compounds, such as
those described here, access to the exoneme-resident enzyme
could potentially allow inactivation of the stored SUB1 long
before its PKG-regulated discharge into the PV. In this work, we
did not determine the intracellular site of PfSUB1 inhibition, so
we cannot state whether inhibition took place within the PV, or
the exonemes, or both. Regardless, by gradual optimization of
the structure and lipophilicity of our compounds we have now
successfully developed potent PfSUB1-inhibitory compounds
that can functionally inactivate PfSUB1 within intact, parasite-
infected RBCs and block egress.
Our conclusion that the intracellular inhibition of PfSUB1
mediated by compound 3j is directly and causally responsible for
the observed block in egress is most clearly supported by the
phenotype of the arrested schizonts, which was indistinguishable
from that resulting from conditional genetic disruption of the
PfSUB1 (12) or PKG gene (27), or following treatment with the
PKG inhibitor C2, with no signs of the morphological changes
that typically precede egress such as PVM rounding or PV
rupture. We cannot rule out the possibility of effects on other
parasite enzymes at the concentrations used to obtain complete
egress inhibition, even in the short-term assays designed to focus
on the short window of the parasite life cycle over which egress
occurs. However, we consider off-target effects unlikely given
that no other parasite serine protease has been implicated in
egress; the only two other subtilisin-like enzymes expressed in
the parasite, SUB2 and SUB3, are respectively dispensable for
egress (28) or nonessential in blood stages (29). The ∼10-fold
higher potency of 3j in the long-term SYBR Green–based par-
asite growth assay (EC50 0.26 μM; Table 1) may be a result of the
fact that this assay captures the combined effects of egress in-
hibition over the course of two erythrocytic cycles in the con-
tinuous presence of the drug, although again off-target effects
cannot be formally ruled out. We anticipate that further
optimization of the PfSUB1-inhibitory potency and membrane
permeability of 3j is highly feasible. Work is already underway to
determine the atomic structure of the 3j-PfSUB1 complex to
facilitate structure-based inhibitor improvement.
Peptidic boronic acids have long-established therapeutic po-
tential, as best exemplified by the widespread clinical use for
multiple myeloma of the proteasome inhibitors bortezomib
(Velcade) and ixazomib, the latter of which is orally bioavailable
in its citric acid form, Ninlaro. The clinical success of these
compounds is in part due to the long drug target residence times
that can be obtained with slowly reversible covalent inhibitors.
Target binding by boronic acid protease inhibitors is generally
time dependent, perhaps further explaining the differences in
potency we observed between the long-term and short-term
cellular assays with compounds 3i and 3j. However, our wash-
out experiments with compound 3j suggest that, once bound to
PfSUB1 in the exonemes and/or PV, it takes at least 30 min for
the level of target engagement to fall below a threshold that
allows successful egress. Examination of the capacity of schizonts
treated with saturating levels of 3j to productively egress and
form new rings following compound washout showed that the
egress block under these conditions was effectively irreversible.
An alternative explanation for this apparently irreversible inhi-
bition of egress by 3j is that the inhibitor is not easily washed out
due to its accumulation in the parasite (or infected RBC) at high
concentrations. We cannot formally rule out this possibility.
However, our ex vivo kinetic analysis of the inhibition of
rPfSUB1 by compound 3j fully supports a slow off rate, with an
estimated bound half-life (t1/2
off) of ∼30 min, very similar to that
of the interaction between bortezomib and the β5 chymotrypsin-
like subunit of the human proteasome (30–32). Even if cellular
accumulation does contribute to the prolonged egress inhibition
exerted by 3j, this is only likely to favor efficacy; indeed, intra-
cellular accumulation is an important component of the mode of
action of the important antimalarial 4-aminoquinoline chloro-
quine (33). While peptide-based drug development can present
challenges for in vivo applications due to metabolic instability,
covalent compounds can be effective even with relatively short
plasma half-lives, since target residence time can be longer than
plasma half-life. Peptidyl boronic acids can anyway have excel-
lent pharmacodynamic properties; for example, the terminal
half-life of ixazomib is ∼9.5 d (a fact that allows weekly dosing of
patients for treatment of multiple myeloma; ref. 34), which is
nearly five times the duration of the P. falciparum asexual blood-
stage lifecycle.
SUB1 has an unusual substrate specificity, which differs subtly
between different Plasmodium species, suggesting that the en-
zyme and its multiple cognate parasite substrates have coevolved
to ensure optimal cleavage efficiency (13). As a result, inhibitors
of PfSUB1 are unlikely to show similar potency against SUB1
orthologs from rodent malaria parasite species such as Plasmo-
dium berghei, making these parasite species unsuitable as model
systems for assessing the in vivo efficacy of our compounds.
Importantly, SUB1 also lacks structural resemblance to any
known human serine protease (16), reducing the likelihood of
substrate-based SUB1 inhibitors displaying toxicity due to off-
target activity against host enzymes. In support of this, we
found here that 3j is only poorly potent against the mammalian
serine proteases examined. Toxicity can be especially problem-
atic where long-term or life-long treatment regimens are re-
quired due to chronic infection (e.g., with HIV). However,
malaria is an acute disease, and long-term therapeutic regimens
are rare; indeed, current standard treatments for uncomplicated
falciparum malaria are just 3 d long. Since SUB1 plays an es-
sential role in the development and release of exoerythrocytic
(liver-stage) merozoites that initiate blood-stage infection (14,
15), medicines based on SUB1 inhibitors have prophylactic as
well as therapeutic potential. Optimized SUB1 inhibitors could
Fig. 5. Schematic indicating the requirement for inhibitors of SUB1 to cross
at least two and up to four membranes to access and inactivate the enzyme
in intraerythrocytic parasites. Inhibition likely occurs either in the PV (route
A), or the exonemes (route B), or both.
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also potentially be combined with inhibitors of other essential
enzymes in the egress pathway, including PKG (35–37) and the
SUB1 aspartic protease maturase plasmepsin X (38–41). Such
combinations could yield additive or synergistic enhancement of
potency and decrease opportunities to select for drug resistance.
In conclusion, we have produced substrate-based peptidic
boronic acids that block asexual blood-stage P. falciparum pro-
liferation through direct, effectively irreversible inhibition of
intracellular PfSUB1. Further investigation of the pharmacoki-
netic properties and structure-based improvement of these
compounds has the potential to generate compounds suitable for
preclinical trials in animal models of malaria.
Materials and Methods
P. falciparum Maintenance and Manipulation. Asexual blood stages of P. fal-
ciparum (clones 3D7 and B11) (42) were routinely maintained at 37 °C in hu-
man erythrocytes at 1 to 4% hematocrit in RPMI 1640 containing Albumax II
(Thermo Scientific) supplemented with 2 mM L-glutamine in a low oxygen
atmosphere using standard procedures (43). Human blood was obtained from
anonymized donors through the UK National Blood and Transplant service
and was used within 2 wk of receipt. No ethical approval is required for its use.
For synchronization, mature schizont-stage parasites were isolated on cushions
of 70% (volume[vol]/vol) Percoll (GE Healthcare) adjusted to isotonicity as
described (43). Routine microscopic examination of parasite growth was per-
formed by fixing air-dried thin blood films with 100% methanol before
staining with 10% Giemsa stain (VWR international) in 6.7 mM phosphate
buffer, pH 7.1.
Generation of the B11-EXP2-mNeonGreen line was achieved by fusing
mNeonGreen to the endogenous C terminus of EXP2 using Cas9-mediated gene
editing, following the methods of ref. 23. A pair of guide RNAs were designed
targeting a region toward the 3′ end of the EXP2 locus (oligo 1: ATTGATATT-
ATGTACAGTATCTGA, oligo 2: AAACTCAGATACTGTACATAATAT) (Sigma). This
oligonucleotide pair was annealed with T4 PNK ligase (New England Biolabs)
and ligated with T4 ligase (New England Biolabs) into the U6 cassette of the
Cas9 vector (pDC2-Cas9_U6-hDHFR) previously digested with Bsb1-HF (New
England Biolabs). The plasmid was propagated under ampicillin selection in
Escherichia coli and sequenced to check for correct incorporation of the guide
(Genewiz). The resulting plasmid was cotransfected into B11 schizonts along
with the repair plasmid pyPM2GT-EXP2-mNG (a kind gift of Josh Beck, Iowa
State University, Ames, IA), linearized with AflII (New England Biolabs). Drug
selection for integration was carried out with 2.5 nM WR99210 (Sigma-Aldrich)
from 24 h posttransfection, and clonal lines of the resulting B11-EXP2-
mNeonGreen line were obtained by limiting dilution cloning and treatment
with 1 μM Ancotil (5-fluorocytosine) before use.
Parasite Growth, Egress, and Invasion Assays. The impact of the peptidic boronic
acids on replication of asexual blood-stage P. falciparum (clone 3D7) was
assessed using a SYBR Green I assay, essentially as described by Smilkstein et al.
(22). Briefly, test compounds (dissolved in dimethyl sulfoxide [DMSO] at con-
centrations ranging from 4 mM to 5 μM) were added in triplicate to wells of
flat bottomed, 96-well microtitre plates (1 μL per well). Wells were then sup-
plemented with 100 μL per well of a P. falciparum parasite culture at 0.1%
parasitaemia, 1% hematocrit. Each assay plate also included DMSO-only con-
trol wells (1% vol/vol), as well as additional control wells containing uninfected
RBCs only. Plates were incubated in sealed, humidified gassed chambers at
37 °C for 96 h to allow the parasites to undergo two entire cycles of eryth-
rocytic growth. Wells were then supplemented with 100 μL 1:5,000 dilution of
stock SYBR Green I (Life Technologies, catalog no. S7563) diluted in 20 mM Tris
HCl pH 7.5, 5 mM EDTA, 0.008% (weight/vol) saponin, 0.08% (vol/vol) Tri-
ton ×100. Plates were agitated to mix, incubated for a further 1 h in the dark
at room temperature, then 150 μL samples from each well transferred to a
fresh white microwell plate and fluorescence quantified using a SpectraMax
M5e plate reader and SoftMax Pro-6.3 software (Ex 485 nm/Em 530 nm). IC50
values were determined from dose–response curves obtained after subtracting
background fluorescence values (obtained from the RBC-only wells) from all
experimental readings.
Short-term egress, invasion, and washout assays were performed essentially
as described previously (27, 28, 42). Briefly, highly synchronous mature Percoll-
enriched schizonts with or without added fresh RBCs (∼5% parasitaemia final)
were incubated with compounds under test or vehicle only (DMSO, 1% vol/
vol). For washout assays, schizonts were treated with C2 or various concen-
trations of inhibitor 3j for 1 to 4 h, then washed extensively (at least four
times) prior to addition to fresh RBCs where required. After incubation at
37 °C for just 1 to 4 h (or overnight for invasion assays) to allow schizont
rupture, cells were pelleted. Clarified culture supernatants were assessed for
extent of hemoglobin release (a measure of schizont rupture) by absorption
spectroscopy at 415 nm as described previously (28) or analyzed by Western
blot using antibodies against SERA5 (7, 11). To quantify generation of new
rings, samples of the cultures were fixed with 4% paraformaldehyde/0.02%
glutaraldehyde and stained with SYBR Green I (Life Technologies) and then
analyzed by flow cytometry on a BD FACSVerse using BD FACSuite software.
Data were analyzed using FlowJo software. All cultures were also routinely
analyzed by microscopic examination of Giemsa-stained thin films to visually
assess parasite morphology.
Time-Lapse and Live Fluorescence Microscopy. Viewing chambers for live para-
site microscopic examination were constructed as previously described (7). All
images were recorded on a Nikon Eclipse Ni light microscope fitted with a
Hamamatsu C11440 digital camera and Nikon N Plan Apo λ 63×/1.45NA oil
immersion objective. For time-lapse video microscopy, differential interference
contrast (DIC) images were taken at 10 s intervals over 30 min while fluores-
cence (mNeon Green) images were taken every 2 min to prevent bleaching.
Time-lapse videos were analyzed and annotated using Fiji (44). For viability
staining using the vital mitochondrial dye MitoTracker Red CMXRos (Ther-
moFisher Scientific; stored as a 10 μM stock in DMSO), the dye was added
(20 nM final concentration) to a suspension of schizonts pretreated for 1 h
with either DMSO (control, 1% vol/vol) or compound 3j (10 μM). The schizonts
were incubated with the dye for 15 min at 37 °C, then washed twice, trans-
ferred to a viewing chamber, and observed immediately by dual DIC/
fluorescence microscopy.
Protease Inhibition Assays: IC50 Calculations and Progress Curve Kinetics. Proteolytic
activity of rPfSUB1 was quantified at room temperature by monitoring cleavage
of the peptidic fluorogenic substrate SERA4st1F-6R12 (Ac-CKITAQDDEESC-OH
possessing tetramethylrhodamine labeling of both cysteine residues) (13). Fluo-
rescence of this peptide is quenched by rhodamine dimerization in the intact
substrate but increases upon cleavage at the internal Q-D bond. Chymotrypsin-
treated rPfSUB1 (expressed and purified as described previously (16) was stored
at −80 °C as a 228 U/mL stock in 20 mM Tris–HCl pH 8.2, 150 mM NaCl, 10%
glycerol, and diluted for use (1:500 or 1:600) in reaction buffer (20 mM Tris–HCl
pH 8.2, 150 mM NaCl, 12 mM CaCl2, 25 mM CHAPS). Peptidic boronic acid in-
hibitors were dissolved in 100% DMSO at 10 or 20 mM, then further diluted in
DMSO to generate stock solutions ranging from 500 to 0.01 μM and then used
diluted 1:100 in the enzyme reactions. All reactions were performed in wells of
white 96-well microwell plates (Nunc); 50 μL diluted rPfSUB1 was preincubated
for 5 min with 1 μL each of the serially diluted boronic acid inhibitors, followed
by addition of 50 μL substrate solution (0.1 μM final). Subsequent fluorescence
increase was continuously monitored using a SpectraMax M5e plate reader and
SoftMax Pro-6.3 software, with readings taken every 5 min for 60 min using
excitation and emission values of 552 and 580 nm, respectively. Initial rates were
calculated over the first 25 min of the assay, during which period progress curves
were linear, and IC50 values were calculated with GraphPad Prism 8.0 using the
nonlinear regression, [inhibitor] versus response, variable slope (four parame-
ters). All experiments were performed in duplicate.
Details of the methodology used to evaluate the effects of compound 3j
on the proteolytic activity of the mammalian serine proteases trypsin, chy-
motrypsin, and elastase are provided in SI Appendix.
Progress Curve Kinetic Analysis of Compound 3j. Progress curves of SERA4st1F-
6R12 cleavage by rPfSUB1 were acquired at seven concentrations of inhibitor
compound 3j over a period of 35 min, during which fluorescence increases in
the absence of inhibitor were linear. The obtained progress curves (four
independent replicates) were fit using GraphPad Prism 8.0 software to the
following time-dependent inhibition equation:
[P]  =   Vs * t  +   ((Vi − Vs)=kobs) * (1 − exp(−kobs * t)). [1]
In the equation, Vi is the initial velocity, Vs is the final steady-state velocity,
and kobs reflects the observed pseudo first-order rate of inactivation. The
obtained kobs values were plotted against compound concentration using a
linear least squares fit. All statistical analysis was carried out using GraphPad
Prism 8.
Covalent Docking. Flexible covalent docking of peptidyl boronic acid com-
pounds into the active site of PfSUB1 (Protein Data Bank: 4LVN)was performed
using the Internal Coordinate Mechanics software (ICM-Pro) package version
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3.9-1c/MacOSX (Molsoft LLC). The inhibitors were drawn using the ICM
chemistry molecular editor and compiled into an sdf docking table. After
adding hydrogen atoms to the structure, the C-terminal region of the SUB1
propeptide (P4 to P1 positions that occupy the SUB1 active site) was used to
define boundaries within the enzyme active site for the docking procedure
and then removed from the active site along with all water molecules prior to
docking. The catalytic histidine (His428, Ne2) was protonated as part of the
catalytic process, resulting from covalent binding of the boron atom ligand to
the active Ser (Ser606 Oγ). The boronic acid covalent mechanism was selected
from the ICM program reactions list. Potential energy maps of the SUB1 re-
ceptor pocket and docking preferences were set up using the program default
parameters. Energy terms were based on the all-atom vacuum force field
ECEPP/3, and conformational sampling was based on the biased probability
Monte Carlo procedure (45). Four independent docking runs were performed
per compound, with a length of simulation (thoroughness) varied from three
to four and the selection of two docking poses. Ligands were ranked according
to their ICM energetics (ICM score, unitless), which weighs the internal force-
field energy of the ligand combined with other ligand-receptor energy pa-
rameters.
Statistical Analysis. All statistical analysis was carried out using GraphPad
Prism 8.0.
Data Availability. All study data are included in the article and/or supporting
information.
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